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Abstract: Methyltransferases (MTases) compose a large family of 
enzymes which have the ability to methylate a diverse set of targets, 
ranging from the three major biopolymers DNA, RNA and protein to 
small molecules. Most of these MTases use the cofactor S-Adenosyl-
L-Methionine (AdoMet) as their methyl source. Given the important 
biological role of methylation, e.g. in epigenetic regulation of gene 
activity and the vast potential of targeted functionalization in biology, 
diagnostics and nanotechnology, it should come as no surprise that 
recent years have seen significant efforts in the development of 
AdoMet analogues with the aim of transferring moieties other than 
simple methyl groups. Two major classes of AdoMet analogues 
currently exist- the doubly-activated and aziridine based molecules- 
each of which employs a different approach for transalkylation, as 
opposed to transmethylation, of the target molecule. In this review, we 
discuss the various strategies for labelling and functionalizing 
biomolecules using AdoMet-dependent MTases and AdoMet 
analogues. We cover the synthetic routes to AdoMet analogues, their 
stability in biological environments and their application in 
transalkylation reactions. Finally, some perspectives are presented 
for the potential use of AdoMet analogues in biology research, 
(epi)genetics and nanotechnology. 
1. Introduction 
Biological systems are complex and  never merely the sum of their 
basic components. Instead, the intricate interplay between 
countless numbers of biomolecules gives rise to new, ‘emergent’ 
properties which could not have been predicted when considering 
each component individually.[1] In that respect, life itself is perhaps 
the most intriguing emergent property of all. Nonetheless, even a 
tiny change in even a single macromolecule can have profound 
effects on a living organism. Such is the case in epigenetic 
regulation of gene activity where small, highly specific 
modifications to DNA, RNA or interacting proteins will result in 
significant modification of biological function. 
Chemists can utilize the inherent specificity of the enzymatic 
machinery involved in epigenetic regulation in order to deliver 
functional- or reporter groups to defined macromolecular targets. 
As such, this review will focus on a subset of the 
methyltransferase (MTase) enzymes, the S-adenosyl-L-
methionine (AdoMet 1, Scheme 1) dependent methyltransferases. 
In nature, these enzymes methylate their targets, which range 
from small molecules to proteins and oligonucleotides. They 
perform this function by binding the methyl-donor, S-adenosyl-L-
methionine (AdoMet 1) and catalyzing the covalent transfer of a 
methyl-group from AdoMet to their target. Moreover, many 
MTases have been shown to be sufficiently malleable such that 
they will perform a similar catalytic transfer of much more 
extended and functional moieties than the methyl-group. This has 
allowed them to become an essential tool in the functionalization 
of the three major biopolymers, RNA, DNA and proteins. The field 
has been the focus of increasing attention and over the past 
decade, several new approaches allowing the incorporation of 
functional chemical moieties onto biomolecules in a site-specific 
manner have been developed. 
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2. Labeling strategies using AdoMet 
dependent MTases 
AdoMet dependent MTases catalyze the transfer of a methyl 
group from their ubiquitous cofactor to a tremendously diverse 
range of biomolecules (Scheme 1). This makes them fundamental 
to a wide variety of biological pathways, ranging from small-
molecule biosynthesis to protein repair, signal transduction, 
chromatin regulation and gene silencing.[2] 
 
 
Scheme 1. Scheme showing the transfer of methyl group from the cofactor 
AdoMet (1) to the substrate by the MTase. 
In order to catalyze methylation, the MTases form ternary 
complexes with their target molecule and AdoMet. These 
complexes involve a network of intermolecular interactions but 
some general principles/chemistries are common to all systems. 
The transferable methyl group of AdoMet is bound to a sulfonium 
center. The molecule is inherently unstable towards nucleophilic 
attack and the methyl group readily participates in substitution 
reactions.[3] This results in a half-life of 17 hours for AdoMet in the 
M.HhaI reaction buffer at pH 7.4, 37°C[4] and the susceptibility to 
nucleophilic attack is instrumental to the function of MTases. A 
mechanism for C5 cytosine methylation by M.HhaI, resulting in 5-
methyl cytosine (5mC) was first described by Santi et al.[5] The 
authors proposed a two-step concerted mechanism which is 
shown in Scheme 2, an enzymatically catalyzed version of the 
Morita-Baylis-Hillman reaction.[5a] In the first step of the reaction, 
cytosine undergoes nucleophilic attack at C6 by the thiol of a 
cysteine residue in the catalytic pocket of M.HhaI. This results in 
the 6-Cys-cytosine compound (C5A). Irreversible nucleophilic 
attack at the transferable methyl group by C5A results in the 
stable intermediate 5-methyl-6-Cys-5,6-dihydrocytosine (MCD) 
and simultaneously converts AdoMet to AdoHcy.[5b] 
Deprotonation and subsequent release of the enzyme of MCD 
restores the aromatic conjugation and results in the DNA 5-
methylcytosine (5mC).[5a] In N6-adenine DNA MTases, the 6-
amino group of adenine forms two hydrogen bonds, which 
increases the electron density of N6 and contributes to its 
activation for nucleophilic attack. 
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Scheme 2. Reaction mechanism of 5-C methylation by M.HhaI (=R).[5a] 
This mechanism is not specific to M.HhaI and was shown to apply 
to many other MTases.[3, 6] An SN2 mechanism is proposed at the 
sp3 carbon center, with SAH acting as a good and stable leaving 
group. This has proven instrumental in allowing the development 
of a large variety of artificial AdoMet analogues. 
2.1 AdoMet analogues 
AdoMet is a structural hybrid of methionine and adenosine for 
which both the R- and the S-diastereoisomers bind similarly to 
MTases. However, only the S-diastereoisomer has the correct 
geometry at the sulfonium center to allow for proper catalytic 
function.[7] In nature, the active S-diastereoisomer is formed upon 
stereospecific reaction of L-methionine (L-Met) and adenosine 
triphosphate (ATP), catalyzed by the methionine 
adenosyltransferase enzymes (MAT).[8] 
The vast majority of artificial AdoMet analogues can be 
categorized into two major groups: aziridinoadenosines and 
doubly-activated AdoMet analogues (Scheme 3). To date, the 
aziridinoadenosines have only been prepared synthetically. 
However, the doubly-activated AdoMet analogues can be 
prepared via either total synthesis or enzymatically, using a 
synthetic methionine analogue and a MAT enzyme.[9] 
 
Scheme 3. DNA labeling using aziridine based or doubly activated AdoMet analogues.
Aziridine based AdoMet analogues 
Aziridine-based AdoMet analogues (Scheme 4)  constitute some 
of the earliest examples of AdoMet analogues and were first 
developed by the group of Weinhold.[10] These AdoMet analogues 
differ from natural AdoMet as their 5’-sulfonium is replaced by an 
aziridine ring (11, Scheme 8). This aziridine group ring-opens as 
a result of a nucleophilic attack from the target compound. Since 
the ‘leaving group’ is conjugated to the transferable moiety in this 
case, following the SN2 reaction mechanism to completion sees 
the transfer of the entire cofactor analogue to the target molecule 
(DNA in Scheme 3).[7] 
Several DNA MTases were found to be capable of transferring 
these compounds to DNA. The process of introducing reporter 
groups (e.g. biotin, 3, Scheme 4) to a variety of DNA sequences 
has been termed ‘Sequence-specific Methyltransferase Induced 
Labeling’ (SMILing). Many different reporters such as e.g. 
fluorescent dyes have been attached to the adenine moiety of this 
aziridine AdoMet analogue for application in DNA labeling.[10b, 11] 
Modelling of the AdoMet-binding pocket from crystallographic 
data showed that steric interactions between the cofactor 
analogues and the enzyme are likely a key factor determining 
compatibility of AdoMet analogues with specific 
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methyltransferases. As an example, modelling of the M.TaqI 
AdoMet binding pocket showed that the 8-position of the adenine 
moiety of a bound cofactor is accessible to the solvent. This 
implies that the enzyme is therefore likely to tolerate cofactor 
analogues that incorporate bulky modifications at this site. 
Successful examples of such bulky modifications to the cofactor 
analogue include an azide group (12, Table 1, SI) and a range of 
fluorophores.[11-12] Pljevaljčić et. al. identified similar opportunities 
for modification of the adenine moiety (6-, 7- or 8- position) for a 
range of MTases from their crystallographic structures. 
Further work on the aziridine-type AdoMet analogues has focused 
on substitutions at the 5’-N to circumvent the production of the 
rather unstable aziridine-based AdoMet analogues.[13] Indeed, 
introduction of an amino acid side chain at the 5’-N position (13, 
Table 1, SI) enhances the MTase catalyzed DNA alkylation and 
generation of small molecule derivatives.[14] These analogues can 
easily be synthesized in situ from the N-mustard precursor, which 
undergoes an intramolecular cyclization to form the aziridine-
based cofactor (Scheme 4). Similarly, inclusion of a functional 
group such as an azide (14, 15, Table 1, SI) or a terminal alkyne 
(4, Scheme 4, 16 and 17, Table 1, SI) enables the use of these 
N-mustard cofactor analogues in bio-orthogonal ligations.[12-13] 
The use of the aziridine-based cofactor analogues for 
transalkylation reactions suffers from several drawbacks. Most 
notably, the transalkylation is not catalytic and stoichiometric 
amounts of the MTase must be used in the reaction. This was first 
observed by Osborne et al. who demonstrated the protein 
methyltransferase 1-catalysed (PRMT1) transalkylation of a 
peptide using a N-mustard-based cofactor. The product of this 
reaction, essentially a peptide with a covalently-bound cofactor 
analogue, is a potent inhibitor for the MTase.[15] Hence, the 
reaction is self-limiting. Furthermore, the aziridine-based 
analogues are very reactive. This makes them prone to rather 
rapid degradation and also results in an increased propensity to 
effect non-specific alkylation, even in the absence of MTases.[7] 
 
 
Scheme 4. Aziridoadenosine based AdoMet analogues.
Doubly activated AdoMet analogues 
MTases have an inherent ability to catalyze the transfer of alkyl 
groups larger than methyl. However, for DNA MTases, the 
transfer rate decreases rapidly with increasing size of the 
transferable moiety (methyl > ethyl > propyl). The reaction occurs 
via an SN2 mechanism with inversion of the configuration at the 
a-carbon next to the sulfur atom.[16] As such, incorporation of an 
unsaturated bond at the b-position can potentially stabilize the 
p-orbital of the a-carbon formed at the intermediate stage of this 
substitution reaction. Weinhold and Klimašauskas were able to 
demonstrate that an allylic or a propargylic carbon-carbon bond 
at the b-position relative to the sulfonium center can restore the 
reaction rate by conjugative stabilization of the SN2 transition state 
(Scheme 5).[17] 
 
 
Scheme 5. Stabilization of the SN2 transition state.[17b] 
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This approach to labeling, using so-called ‘doubly-activated’ 
cofactor analogues has been termed ‘methyltransferase-directed 
Transfer of Activated Groups’ (mTAG).[18] Unlike aziridine based 
labeling, mTAG is a truly catalytic process and does not require 
stoichiometric amounts of the MTase.[17b] Even though multiple 
turnovers per minute can be achieved, the process is still typically 
an order of magnitude slower than the equivalent methyl-
transfer.[17b] 
AdoMet analogues with alkyl, alkenyl (19, see Table 2, SI) and 
alkynyl (20, see Table 2, SI) side chains have been prepared and 
successfully applied in mTAG.[17] 
The approach offers a simple way to label targets with a functional 
group that can be used for further ligation of more complex 
moieties. For example, incorporation of different transferrable 
amine moieties (21[4, 18], 22[4, 19], 23[4, 19b] Table 2, SI), can be 
followed by a -coupling reaction with the NHS-ester of an amine-
reactive probe.[18] In addition, several examples exist on the 
application of AdoMet analogues with a transferrable terminal 
alkyne (5[20], Scheme 6, 20[20g, 20h], 24[20b, 20c, 20g], and 25[4, 19b], 
Table 2, SI) or azide (26[20g, 21], 27[4]). Transferred alkynes and 
azides can be further functionalized using the bio-compatible and 
highly-efficient azide-alkyne cycloaddition reaction (one of the 
‘click’ series of reactions). However, some of these analogues, 
such as compound 20 (Table 2, SI), featuring a terminal alkyne, 
are highly unstable.[4, 20g, 20h] Other AdoMet analogues, such as 
the AdoEnyYn compound (5, Scheme 6), are more stable, making 
them more suitable for use in bio-orthogonal ligation.[20b-h] 
Ketones are yet another interesting transferrable moiety as they 
can be used to react with hydroxylamines and hydrazides. This 
was demonstrated with AdoMet analogue 28 (Table 2, SI), which 
was successfully transferred to DNA and subsequently used for 
coupling with a hydroxylamine coupled to a fluorophore.[22] Finally, 
AdoMet analogues directly incorporating a fluorescent dye allow 
for single-step, direct labeling reactions. One such example in 
which a TAMRA dye was coupled to the AdoMet analogue (6, 
Scheme 6) and subsequently used for labeling reactions was first 
described by Grunwald et al.[23] 
 
 
 
Scheme 6. Doubly activated AdoMet analogues. 
2.2 Stability of AdoMet analogues 
AdoMet analogues are prone to spontaneous decomposition in 
aqueous environments through a range of different pathways 
(Scheme 7).[4, 24] Reversible racemization (route a) to the 
(R)-diastereomer of AdoMet is also common and  can result in the 
formation of an inactive AdoMet analogue. The presence of the 
sulfonium center activates the adjacent carbon atoms towards 
decomposition reactions. In alkaline conditions, deprotonation at 
the 5’-C occurs (route b), which results in formation of adenine 
and S-ribosylmethionine. Under more acidic conditions, 
intramolecular attack of the a-carboxylate group onto the g-C of 
the methionine group (route c) yields methylthioadenosine (MTA) 
and homoserine lactone (HSL). In the case of AdoMet, no 
nucleophilic attack is observed at the methyl group, but this 
changes when considering AdoMet analogues with extended 
chains containing a triple bond in b-position, relative to the 
sulfonium center. The partial positive charge at the 1”-C increases, 
making it more susceptible to nucleophilic attack (route d). When 
electronegative groups (e.g. X= NH2) are in close proximity to the 
triple bond, this can lead to a higher electron deficiency at both 
4”-C and 1”-C, which enables the addition of water (route e) at 
both and results in the hydrated compound showing almost no 
reactivity towards most DNA MTases and protein MTases.[4, 24]
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Scheme 7. Decomposition pathways of (S,S)-AdoMet (analogues). a: Inversion at the sulfonium center of (S,S)-AdoMet results in (R,S)-AdoMet. b: deprotonation 
at the C-5’ and subsequent elimination of adenine base to give S-ribosylmethionine. c: nucleophilic attack of the a-carboxylate onto the g-carbon of methionine 
delivers HSL and MTA. d: nucleophilic addition at 1”-C. e: addition of water on the 2”-C or 4”-C position.
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For a pH of 7.5 and a temperature of 37 °C, the rate constants for 
racemization, cleavage to HSL/MTA and hydrolysis to adenine 
/S-ribosylmethionine were reported to be 1.8 x 10-6 s-1, 4.6 x 10-6 
s-1 and 3 x 10-6 s-1 respectively. The hydrolysis rate shows a 
significant decrease at lower pH values.[25] 
Recently, Huber et al. developed novel AdoMet analogues lacking 
the N7 of the adenine moiety and further omitting the carboxylic 
acid of the amino acid chain in favor of a tetrazole ring. This 
makes them less likely to decompose through both pathways b 
and c and restricts epimerization at the sulfonium center.[26] 
To improve the stability and reactivity of the AdoMet analogues, 
several molecules have been studied where sulfur is replaced 
with another chalcogen, such as selenium (SeAdoMet, 7, Figure 
1) and tellurium (TeAdoMet, 8, Figure 1). For AdoMet, three 
decomposition pathways are common: racemization to the 
inactive diastereomer, deprotonation of the 5’-C to yield S-
ribosylmethionine and adenine or intramolecular nucleophilic 
attack of the carboxylate group to result in HSL and MTA. 
SeAdoMet (7, Figure 1) was found to decompose via two of these 
reactions whereas the tellurium analogue TeAM (8, Figure 1) was 
inert to all three pathways.[24] It could be shown that the trend in 
electrophilicity of these AdoMet analogues followed SeAdoMet > 
AdoMet > TeAdoMet and that the 5’-C acidity follows the series 
AdoMet > SeAdoMet> TeAdoMet.[27] Selenium analogues are 
therefore both more reactive towards nucleophilic attack, making 
them better suited as cofactors for transalkylation and more stable 
towards deprotonation of the 5’-H (pathway b, Scheme 7). As a 
result, they have been subject of extensive investigation. 
Weinhold et al. have developed SeAdoYn (9, Figure 1) as a 
cofactor for protein methyltransferase directed fluorescent 
labeling of proteins. This analogue showed improved reactivity 
and higher stability toward hydrolysis compared to the similar 
sulfur-containing AdoEnYn and AdoYn analogues.[20h] 
Comparative decay studies of propargylic SeAdoYn (9, Figure 1) 
and ProSAM (20, Table 2, SI) analogues showed that 
decomposition of the ProSAM compound results firstly in the 
hydrated product (keto byproduct, 28, Table 2, SI), which further 
decomposes to the thioether. However, the SeAdoYn follows a 
different mechanism and directly forms the selenoether.[20h, 28] 
SeAdoYn was used as a substrate for transalkylation by a large 
variety of wild-type MTases, which is in contrast with many of the 
AdoMet analogues, with larger transferable groups, that were only 
active with mutated MTases.[9b, 19a, 20h, 28-29] 
The group of Luo has also demonstrated that selenium 
substitution can result in increased reactivity of the sulfur-
centered AdoMet analogues when applied as substrates for the 
protein MTases. Their study shows that the decomposition rate of 
SeAdoMet is 10-fold higher than that of AdoMet, but the protein 
MTase-catalyzed transalkylation reaction is only 3-5 fold faster for 
the SeAdoMet analogue. Hence, the authors suggest that the 
protein MTase-catalyzed reaction rates are not determined solely 
by the strength of the chalcogen-carbon bond, but are likely 
caused by other factors.[28, 30] Interestingly, the study also 
suggests that the b-sp2 carbon, which is essential for activity with 
S-alkyl AdoMet analogues, is likely not required for some protein 
MTases when Se-alkyl AdoMet analogues are used.[30] 
 
Figure 1. Chalcogen containing AdoMet analogues. 
2.3 Synthesis of AdoMet analogues 
The first example of the synthesis of aziridine-based AdoMet 
analogues was described by Pignot et al. in 1998 who focused on 
the development of aziridine-based cofactor analogues.[10a, 31] 
N-Adenosylaziridine was synthesized using a nucleophilic 
substitution of the tosylate group in 5’-deoxy-5’-tosyladenosine 
with aziridine and subsequently activated as an alkylating agent 
by protonation of the nitrogen atom in the aziridine ring (Scheme 
8).[10a] 
 
 
Scheme 8. Synthesis of N-Adenosylaziridine AdoMet analogue. Step 1: 
Nucleophilic substitution of the tosylate group in 5’-deoxy-5’-tosyladenosine with 
aziridine. 
The ring-strain in this three membered heterocycle makes it 
susceptible to nucleophilic ring-opening, which is further 
facilitated by nitrogen quaternization. This aziridine based 
AdoMet analogue can be used for the introduction of different 
functional or reporter groups through modification of the adenine 
moiety. One such example shows the attachment of a dansyl 
fluorophore at the adenine 8-position.[11] The synthesis starts from 
8-bromo-2’,3’-O-isoporpylideneadenosine, which was treated 
with diaminobutane to introduce a flexible linker and was in a few 
steps (substitution and deprotection) converted to the 
N-adenosyl-aziridine derivative. A similar route has been used to 
prepare the N-mustard precursors of the aziridine-based AdoMet 
analogues (Scheme 4).[32] 
These aziridine-based AdoMet analogues suffer from a long- and 
low yielding-synthetic route.[10, 12b, 13-14] Townsend et al. have 
reported improved synthetic routes for the synthesis of N-
chloromustard-substituted adenosines using reductive amination 
as the key step and have also demonstrated the synthesis of a 
photo caged derivative, which benefits from increased stability 
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compared with standard aziridine-based cofactors and is readily 
activated as a cofactor using UV-irradiation.[33] 
Doubly-activated AdoMet analogues are typically synthesized by 
combining S-adenosyl-L-homocysteine (AdoHcy, 2, Scheme 9) 
with an excess of strong electrophiles, e.g. alkyltriflates or 
alkylbromides, in acidic conditions.[34] The first chemical synthesis 
of the diastereomers of AdoMet from AdoHcy was published in 
1959.[35] In acidic environment, the propensity for nucleophilic 
attack by e.g. AdoHcy amines, hydroxyls or the carboxyl acid is 
strongly reduced, leaving the thioether as the sole reactant.[17a] 
Both the (R)- and the (S)-epimer are formed during this SN2 
reaction. However, as only the active (S)-epimer can be used in 
transmethylation reactions, a separation of the diastereomers is 
preferable. Reverse-phase HPLC (RP-HPLC) is commonly used 
in efforts to separate the diastereomers. This, however,  remains 
challenging. 
 
 
Scheme 9. Synthesis of doubly activated AdoMet analogues 
The synthetic routes to AdoMet analogues are not trivial. In 
addition, these compounds often display limited stability. As a 
result, there have been several attempts have to prepare both 
AdoMet and its analogues enzymatically.  
AdoMet itself can be obtained by isolation from yeast, grown in 
media supplemented with L-methionine.[8b] Small-scale[8a, 36] 
(µmol) enzymatic syntheses of AdoMet from ATP and 
L-methionine (L-Met) as well as larger scale[8b] (mmol) synthesis 
have been reported. The AdoMet formation is catalyzed by 
L-methionine S-adenosyl transferase enzyme (MAT or AdoMet 
synthetase) in a two-step fashion where the complete 
tripolyphosphate (TPP) chain of ATP is cleaved and subsequently 
hydrolyzed to pyrophosphate (PPi) and phosphate (Pi). The 
enzymatic synthesis results in high yields of the preferred (-)-
epimer (Scheme 10, top).[36a, 37] 
Recently, several groups have demonstrated enzymatic synthesis 
of AdoMet analogues as well.[9, 38] The group of Thorson tested a 
range MAT enzymes for their ability to catalyze the formation of 
several AdoMet analogues. They tested a library of forty-four non-
native S/Se l-Met analogues with five different MATs. Of these, 
human MAT II was the most permissive. Furthermore, the 
synthesized analogues could be successfully used in the 
alkylation of small molecules (indolocarbazoles).[9b] The group of 
Burkart demonstrated the chemoenzymatic synthesis of several 
AdoMet analogues using either a fluorinase (FDAS) from 
Streptomyces cattleya or a chlorinase (SalL) from marine 
bacterium Salinaspora tropica.[38-39] Both halogenases are known 
to catalyze the breakdown of AdoMet, resulting in L-Met and 
fluoro-5’-deoxyadenosine (FDA) or 5’-chloro-5’-deoxyadenosine 
(ClDA). However, the reaction can be reversed at low 
chloride/fluoride and high L-Met concentrations (Scheme 10, 
bottom). This enzymatic pathway can also be exploited using 
various L-Met derivatives for the enzymatic synthesis of AdoMet 
analogues.[9a, 38, 40] but it should be noted that decreased activity 
of the L-Met analogues with increasing size of the L-Met analogue 
was observed.[40] 
 
 
Scheme10. Enzymatic AdoMet synthesis using SalL and MAT 
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2.4 Methyltransferases 
Methyltransferases are typically categorized in 5 distinct families 
(classes I-V) based on structural similarities.[2a] Of these, Class I 
MTases, are by far the largest group. They catalyze the majority 
of methylation reactions and include all DNA MTases, some 
protein MTases and RNA MTases.[2a] The largest group of protein 
MTases are the protein lysine MTases, and together with the 
protein arginine MTases, they play an important role in histone 
modification and thus ultimately in gene transcription. Most of the 
work in the past decade using modified AdoMet analogues has 
focused on class I MTases and class V MTases, which are also 
the focus of this review. Other, less common, classes include the 
MetH reactivation domain (class II), precorrin-4 MTases (class III) 
and the SPOUT family of RNA MTases (class IV).[2] 
While the MTases share little sequence similarity, they do share 
a highly conserved structural fold. The core element of this 
conserved fold are seven stranded β-sheets with three helices on 
each side, a structural feature commonly referred to as the 
Rossman fold.[2b, 41] This core is shared among MTases that act 
on all different substrates, ranging from small molecules to DNA 
and proteins.[3, 42] This structural similarity suggests that the 
labeling reactions with AdoMet analogues are universal and 
applicable across the entire range of MTases. 
In labeling reactions, wildtype MTases are most frequently used 
in combination with an AdoMet analogue. However, in some 
cases this is not possible because the native fold of the MTases 
is incompatible with the AdoMet analogue. This could be due to 
bulky groups on the AdoMet analogues that prevent a good steric 
fit or disruption of the needed binding interaction to the AdoMet 
binding pocket. In these scenarios it could prove useful to 
engineer the AdoMet binding pocket for a more favorable 
interaction with the AdoMet analogues, for example by directed 
evolution of the MTase.[43] 
In other cases, it might be preferable to use an MTase that 
interacts more readily with the AdoMet analogue rather than the 
natural AdoMet. For example, when using the labeling reaction in 
live cells in the presence of AdoMet. In this scenario it would be 
useful to engineer the AdoMet binding pocket such that the 
enzyme prefers the AdoMet analogue over the natural AdoMet. A 
typical approach in such a case is to aim for a ‘bump-and-hole’ 
strategy.[44] 
 
DNA transalkylation 
In bacteria, the DNA MTases play a role in defense of the 
bacterium against viral invasion by enabling the distinction 
between their host genome and invading viral DNA to be made.[6, 
45] In eukaryotic cells the MTase’s main role is in the regulation of 
genes.[6] DNA methyltransferases can be subdivided depending 
on their target for modification (cytosine C5, cytosine N4 or 
adenine N6). Of these groups the cytosine C5 and adenine N6 
MTases are found in many species of fungi, bacteria and protozoa, 
while the cytosine N4 MTases occur only in bacteria.[6, 46] 
The DNA MTases typically recognize short, palindromic DNA 
sequences (2-8 bases long). Ordinarily, the target base for 
methylation lies buried within the DNA helix and as a result, the 
DNA MTases extrude this base from the DNA duplex, flipping it 
into the enzyme’s catalytic pocket, where transmetylation occurs 
(Figure 2).[47] The byproduct of this catalysis, S-adenosyl-L-
homocysteine (AdoHcy, 2, Scheme 9), is subsequently released 
from the AdoMet binding pocket and, in cells, digested by a 
AdoHcy hydrolase enzyme.[48] 
 
 
Figure 2. Base flipping mechanism. Most of the work on DNA MTases with 
AdoMet analogues is based on M.TaqI, a DNA MTase from a thermophilic 
bacteria. 
DNA MTases were the first MTases that were shown to catalyze 
transalkylation reactions using the AdoMet analogues. Part of the 
reason for this is likely the ease with which the progress of the 
labeling reaction can be followed. Every bacterial MTase has a 
partner restriction endonuclease that cleaves DNA at the same 
site targeted by the MTase. However, if that site is methylated (or 
alkylated) cleavage is prevented. This can be exploited to readily 
confirm the activity of the methyltransferase with the AdoMet 
analogue using gel electrophoresis. 
The first example of a transalkyation reaction using an AdoMet 
analogue and a DNA MTase was the aziridine transfer with the 
M.TaqI DNA MTase in 1998.[10a]. Many aziridine analogues have 
subsequently been successfully transferred to DNA by, for 
example, adenine DNA MTases M.EcoRI[12b] and MBsecI[49] and 
cytosine DNA MTases such as M.HhaI[12a] and M.SssI[14a]. In 
these cases functional moieties (including fluorophores[11]) were 
placed on various locations of the aziridine cofactor. The 
aforementioned study by Pljevaljcic et. al., which models cofactor 
binding pockets of several DNA MTases together with the cofactor 
analogues, concludes that 4 of the 6 screened enzymes (M.TaqI, 
M.RsrI, M.DpnM, M.PvuII) are likely to tolerate cofactors carrying 
bulky modifications at the 8-position of the cofactor’s adenine 
moiety. For M.HhaI and M.MboII the 7 or 6 positions of that same 
adenine moiety appear to be feasible sites for the attachment of 
bulky modifications.[10b] However, to the best of our knowledge, 
only the M.TaqI and M.HhaI enzymes have been shown to 
transfer an aziridine AdoMet analogue to DNA. Unpublished work 
in our lab failed to show any transfer with the M.PvuII enzyme and 
aziridine analogues carrying modifications at the adenine 6-, 7-, 
and 8-positions. 
As previously mentioned, the aziridine AdoMet analogues suffer 
from some disadvantages, which has inspired Weinhold and 
Klimašauskas to develop the doubly-activated AdoMet analogues. 
These cofactors have been employed in successful 
transalkylation reactions with several DNA MTases, with either 
adenine or cytosine as a target base. A comprehensive overview 
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can be found in Table 1. The attachment of a functional or 
fluorescent group to the DNA can be achieved using a second 
chemical coupling reaction, such as amine to NHS ester[19c] or 
click-chemistry-based conjugation.[20f] Alternatively, like the 
aziridine cofactors, the fluorescent group can be synthetically 
coupled to the cofactor, thus allowing one-step transfer of the 
fluorescent groups to the DNA substrate. This approach was first 
demonstrated with the DNA MTase M.TaqI.[23] 
Rates of the transalkyation reaction with the doubly-activated 
AdoMet analogues have been dramatically improved by 
engineering of the cofactor binding pocket of the cytosine C5 
MTases.[19d] Three amino acid side chains were selected based 
on their potential steric interaction with the cofactor, and replaced 
with shorter residues (two residues were replaced with alanine, 
while one residue was replaced with the smaller polar residue 
serine). The mutants showed a significant improvement in both 
binding affinity and the transfer rate of the AdoMet analogues, 
relative to the wild-type M.HhaI. In general, this effect was more 
marked for the longer cofactor analogues with transferrable 
groups with longer alkyl-chains than those with shorter chains. 
Furthermore, the mutant enzymes show a significant reduction in 
the methylation rate with the natural cofactor AdoMet. The binding 
constant of the enzyme with the natural cofactors AdoMet and 
AdoHcy was reduced as well. The weaker binding of AdoHcy may 
contribute to the increased catalytic efficiency of the AdoMet 
analogues. 
Two of three mutations were located within the highly conserved 
sequence motifs of M.HhaI and were readily mapped to locations 
on other C5- DNA MTases. Indeed, the same mutations were 
successfully applied to cytosine-5 MTases M.HpaII and 
M2.Eco31I, and later to the CpG-specific MTase M.SssI.[50] 
However the same mutations did not result in an improved 
labeling with M.BsaHI.[20f] 
 
Table 1. DNA MTases (on the right) shown to be compatible with various AdoMet analogues and the functionalities implemented on the AdoMet analogue 
  MTAG Aziridine 
 Target Alkyl Alkyne Amine Azide Fluo None Alkyne Azide Biotin Fluo 
M.TaqI TCGA [17] [17b,	20f], [18]  [23] [10-11,	12b,	
14a] 
[13,	14b] [12b,	14b] [12b,	49a] 
[10b,	11,	
51] 
M.HhaI[a] GCGC [17b]  
[18,	19c,	
19d] 
[4]  [12b] [14b] [12b,	14b] [52]  
M.SssI[a] CG   [50] [50]       
M.BseCI ATCGAT         [49]  
M.BcnIB[a] CCSGG [17b] [17b]         
M2.Eco31I[a] GGTCTC  [19d] [19d]        
M.EcoRI GAATTC      [12b,	14a] [13] [12b]   
M.HpaII CCGG  [19d] [19d]   [12b,	14a]     
M.XbaI TCTAGA  [20f]         
MFokI GGATG  
and  
CATCC 
 [20f]         
[a] Mutant enzyme with improved activity in the presence of a AdoMet analogue  
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RNA transalkylation 
In this section we present a brief overview of the application of the 
of the RNA methyltransferase enzymes, which have been shown 
to catalyze transalkylation, using AdoMet analogues, of RNA. 
Early studies show some promise in this area but all have been 
realized in vitro using synthetically-prepared or in-vitro transcribed 
RNA substrates. Whether the methyltransferases can replace 
existing antibody-based approaches for targeted labelling or 
capture of RNA-based substrates remains an area for further 
investigation. 
The first example of an RNA methyltransferase-directed 
transalkylation was with the tRNA methyltransferase, Trm1. [20d] 
This enzyme has been shown to catalyze the transalkylation of 
the N2 of guanosine 26 in tRNAPhe using a doubly-activated SAM 
analogue with an alkyne functionality. The modified tRNA was 
subsequently fluorescently labelled using the copper catalyzed 
azide-alkyne cycloaddition reaction (one of the ‘click’ reactions), 
in order to generate fluorescently labeled tRNA. 
Using in vitro reconstitution of an archaeal box C/D small 
ribonucleoprotein RNA 2’-O-methyltransferase (C/D RNP) 
Tomkuvienė et al. were able to demonstrate transalkylation of in 
vitro transcripts of tRNA and pre-mRNA molecules. The C/D RNP 
complex includes a guide RNA molecule that is used to direct the 
specificity of the C/D RNP to these non-natural substrates. Again, 
in a second reaction, the alkylated RNA molecules were 
fluorescently labeled using the copper catalyzed azide-alkyne 
cycloaddition reaction.[19a] 
Functionalization of both miRNA and small interfering RNA 
(siRNA) has been described by Plotnikova. et. al.[19b] Here, the 
HEN1 2’-O-methyltransferase from Arabidopsis thaliana was 
used to direct transalkylation to the 3’-terminal nucleotides of 
small double stranded RNA molecules. In fact, this study 
demonstrates the direct transfer of biotin to the 3’-ends of small 
RNA duplexes and their subsequent isolation using streptavidin-
coated beads.[19b] 
 
Protein transalkylation 
The two most common AdoMet dependent protein MTases are 
protein arginine MTases and protein lysine MTases.[53] However, 
there are some protein MTases which target other sites such as 
other peptidyl chains, N- or C-termini.[54] The main targets of 
arginine and lysine protein MTases are histones, where 
methylation of the histone is associated with repression of 
transcription.[55] Besides histones, numerous other proteins have 
also been targets of methylation, where they play a role in many 
physiological paths such as signal transduction and protein 
translocation.[56] Because of the close role of histone methylation 
with repression of transcription, protein MTases have been 
implicated in cancer, neurodegenerative and other diseases.[57] 
One notably early study in 2001 demonstrated that a mutant of 
the yeast MTase Rmt1 was selectively inhibited using 
N6-substituted AdoMet analogues. This was the first successful 
demonstration of the bump-hole technique as a means to develop 
selective combinations of mutant methyltransferase enzymes and 
tailored AdoMet analogues.[44] The aziridine-based cofactor 
analogues and the PRMT1 protein methyltransferase have been 
successfully employed for protein transalkylation.[15, 58] The 
doubly-activated (mTAG) cofactors were first employed in protein 
transalkylation reactions by Peeters et. al.[20e] This, and a later 
study, describe the transfer of an alkyne group to the target of the 
two histone H3K9 protein MTases Dim-5 and SETDB1.[59] 
The group of Luo, have developed combinations of several 
AdoMet analogues and engineered protein MTases to enable bio-
orthogonal targeting of transalkylation reactions in cells. Their 
work is covered in detail in a recently published review[7] but we 
provide a brief overview here. The focus of their work has been 
the human protein MTases G9a (Also known as EuHMT2), GLP1 
(also known as EuHMT1) and PRMT1 (for a complete overview 
see table 2). Enzyme-directed transalkylation reactions  using 
azido-AdoMet with engineered G9a and GLP1[21, 60] and an 
alkyne-AdoMet with engineered G9a[20c] and PRMT1 have been 
demonstrated.[20g] Additionally, a Selenium-based SAM analogue 
with an alkyne linker was effectively employed in transalkyation 
reactions directed and catalyzed by the native protein MTases 
GLP1, G9a and SUV39H2.[28, 60-61] 
An extensive study with 8 native enzymes showed limited 
transalkylation by the 3 wild type protein MTases G9a, GLP1 and 
SUV39H2 using an allyl-AdoMet analogue, and a complete 
absence of activity with the bulkier AdoMet analogues.[62] 
However, a single mutation in these three enzymes was shown to 
have a dramatic impact on their ability to catalyze transalkylation 
reactions and, furthermore, led to a significant reduction in the 
rate at which they performed methylations, using AdoMet. Hence, 
these mutants were found to be capable of performing 
transalkylation reactions with synthetic AdoMet analogues in the 
presence of native AdoMet (e.g. in cell lysates).[63] In a 
subsequent study, Islam et. al. investigated the function of the 
mutations (Y1211A in EuHMT1, Y1154A in EuHMT2) which 
further improved the enzymatic transalkylation rates using the 
AdoMet analogues. The residues targeted for mutations were 
branded as gatekeeper amino acids that had blocked access to 
the cofactor binding pocket for the bulkier, synthetically-prepared 
AdoMet analogues.[20b] 
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Table 2. protein MTases shown to be compatible with various AdoMet analogues and the functionalities implemented on the AdoMet analogue. 
 MTAG Aziridine 
 None Alkyne Azide None Alkyne Azide 
PRMT1[a]  [20g,	20h]  [15,	58] [58] [58] 
PRMT3  [20a]     
Dim-5  [20e,	20h]     
GLP1 
(EuHMT1) [a] 
[20b] [59]     
G9a 
(EuHMT2) [a] 
[20b] [20b,	21,	28,	62,	64]     
METTL21A  [20b,	20c,	20h,	21,	28-29,	62,	
64] 
[60]    
METTL10  [29a]     
Set7/9  [29a]     
PrmC  [20h,	49d]     
SUV39H2  [20h]     
  [28,	62]     
[a] Mutant enzyme with improved activity in the presence of a AdoMet analogue 
Small-molecule transalkylation 
Small-molecule or natural product methylation is ubiquitous 
across all branches of the tree of life. Many AdoMet dependent 
MTases targeting natural products (NP-MTases) exist and they 
can generally be categorized based on their preference for 
oxygen, nitrogen, sulfur or carbon as their nucleophilic 
substrate.[65] As such, NP-MTases participate in the modification 
of a large numbers of structurally diverse small organic molecules, 
affecting their bio-availability, activity and reactivity in processes 
ranging from metabolism to signaling and biosynthesis.[65b] Many 
NP-MTases could be shown to feature a Rossman-like fold 
structural motif that is often extended by additional domains. 
These additions to the core enzyme structure ultimately allow 
individual NP-MTases to display wide ranging substrate 
specificity. Because of their versatility, NP-MTases, used in 
combination with AdoMet or its artificial analogues are particularly 
appealing in biocatalysis and production of fine chemicals where 
they can help to unlock synthetic routes that would not be 
accessible using traditional methods. Excellent overviews of such 
efforts are provided elsewhere.[2b, 66] 
 
3. Current and future applications 
The ever expanding repertoire of doubly-activated cofactor 
analogues and suitable natural- or engineered MTases has 
provided us with a unique and versatile set of tools for labeling the 
three major biopolymers.[67] While their most immediate 
applications might be found in the study of biological mechanisms 
underlying epigenetic modification and signaling, it would be hard 
to overstate the potential uses of such a highly specific 
biomolecular toolkit in all areas of research where directed, site 
specific labeling is required. In the following paragraphs, a 
selection of these applications is presented. 
3.1. Selective enrichment of biomolecules 
Specific enrichment of genetic material is particularly important in 
the context of high throughput, high coverage sequencing 
efforts.[68] Indeed, even though next-generation sequencing 
technologies have made whole genome sequence information 
relatively easy to obtain, the sheer amount of data produced can 
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be a confounding factor. Moreover, diseases such as cancer or 
viral infections will result in sub populations of cells or even single 
cells with a distinct genetic makeup against the background of the 
entire population, so called sub clonal genetic heterogeneities.[68b] 
By labeling target DNA with e.g. a biotin-containing AdoMet 
analogue, it can subsequently be captured using e.g. streptavidin 
functionalized particles.[19b] Alternatively, biomolecules can be 
labeled using clickable AdoMet analogues and coupled to azide 
or alkyne beads. This method was recently demonstrated using 
lambda DNA labeled with M.TaqI and a cofactor featuring a 
terminal alkyne.[69] A different study showed capturing of DNA by 
labeling with either amine or azide moieties.[50] Subsequently, the 
molecules were coupled to the surface of particles via either a 
biotin NHS-ester adduct or a biotin dibenzocyclooctyne moiety. 
The use of MTases in the detection of non-methylated genomic 
DNA has been demonstrated by the group of Klimašauskas.[50] 
The MTase M.SssI was used to label DNA featuring regions of 
unmethylated CpG sites with a cofactor that could be used to 
biotinylate the DNA. This biotinylated DNA could subsequently be 
selectively captured for downstream analysis using micro-array 
screening or sequencing.[50] 
Next to the identification of genomic regions featuring low 
methylation, MTase based labeling strategies could also be 
applied to the separation of DNA of interest from a background of 
other genomic material in the sequencing of the Neanderthal 
genome. Here, environmental DNA of mostly bacterial origin 
needed to be removed. To achieve this, the researchers used the 
fact that mammalian DNA is frequently methylated at CpG sites, 
which occurs far less frequently in bacterial DNA. Treatment with 
restriction enzymes that specifically target CpG sites, largely 
destroys the bacterial DNA, leaving the endogenous DNA 
intact.[70]  
Capturing biomolecules is not just limited to DNA, but can 
potentially also be used to specifically enrich RNA or proteins. 
Indeed, it has been shown that proteins can be captured by 
coupling a biotin tag to proteins with click chemistry.[71] This 
approach has been used by the group of Luo for the specific 
targeted capturing of proteins using MTase-based labeling 
(Figure 3).[20a, 20b, 28, 64]  
 
Figure 3. Schematic illustration of using AdoMet analogue as a reporter of 
protein methylation. The AdoMet analogue can be utilized by endogenous 
methyltransferases to label cellular proteins with an alkyne moiety. The modified 
proteins can then be coupled to a fluorescent tag using CuAAC for further 
characterization. From Islam et al.[28] 
Specifically, an AdoMet analogue with alkyne functionality was 
used for targeted labeling of protein MTase targets. Then, biotin 
with an azide group was coupled to the proteins using click 
chemistry, and the proteins were subsequently captured using 
streptavidin beads. The presence of a cleavable azo-linker 
between the azide and biotin made it possible to separate the 
captured proteins from the beads after treatment with sodium 
dithionite (Na2S2O4). Finally, the strategies presented here might 
also be a useful tool for the assembly of biomolecular 
structures[49b] and positioning of nanoparticles.[49a] 
3.2 Genomic analysis 
DNA mapping 
The discovery of sequence specific restriction endonucleases 
(REases) enabled DNA sequence analysis long before the advent 
of single nucleotide sequencing.[72] When a DNA sample is 
digested by a known panel of REases, the ensuing characteristic 
fragment lengths can be analyzed using agarose gel 
electrophoresis, resulting in a ‘DNA fingerprint' with applications 
in e.g. forensics.[73] Schwarz et al. further refined the technique by 
binding linearized DNA molecules to a surface prior to digestion, 
resulting in restriction or sequence ‘maps’ where additional 
information is contained in the relative location of the different 
fragments.[74] Site specific incorporation of fluorescent labels, 
rather than actual restriction of the DNA has further contributed to 
increase the information content of sequence maps.[75] Whereas 
nicking endonucleases and corresponding fluorescent nucleotide 
analogues were initially used here, they have since been 
supplanted by MTase-directed labeling, offering a number of 
advantages. Firstly, use of MTases keeps the DNA backbone 
intact, improving the stability of the DNA molecules and 
minimizing unwanted fragmentation. Furthermore, DNA MTases 
allow for a more direct labeling approach compared to nicking 
endonucleases, increasing the efficiency of transfer. Finally, 
through careful choice of the DNA MTases, high densities of 
labeling can be achieved. Indeed, a DNA MTase with a 4 base 
recognition sequence applied to a random DNA sequence  would 
result in 1 label every 256 base pairs (44). 
The past couple of years several approaches to DNA mapping 
using DNA MTases have been developed and excellent reviews 
on the subject exist.[76] These approaches can be roughly 
categorized in DNA mapping in nanofluidic channels and DNA 
mapping using super resolution microscopes (Figure 4). 
MTase mapping in nanofluidic channels was first demonstrated 
by the group of Ebenstein[23] Here, phage T7 and phage Lambda 
DNA were labeled using the methyltransferase M.TaqI 
(recognition sequence: 5’-TCGA-3’) and a synthetic AdoMet 
analogue carrying the fluorophore TAMRA. The labeled 
molecules were subsequently stretched in nanochannels after 
which intensity profiles were extracted using a fluorescence 
microscope. Because of the high density of fluorophores in 
combination with the use of diffraction limited microscopy, the 
exact location of labels could not be determined. Instead, the 
obtained intensity profiles were matched to several in silico 
generated intensity maps by cross correlation of both profiles. 
Thresholding the cross correlation scores allowed for the efficient 
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matching of bacteriophages to the correct sequence. More 
recently, the same group also demonstrated the ability to perform 
genomic mapping with sub-diffraction limit resolution in silicon 
nanochannels, greatly enhancing the information density.[77] 
 
 
 
Figure 4: Illustration of the two main methods for reading the distribution of fluorophores on DNA molecules. A. For high resolution localization of fluorophores on 
the DNA, the DNA needs to be rigidly attached to the surface. B. For rapid imaging of DNA, the DNA molecules can be flown through nanochannels where they are 
elongated and subsequently, the intensity pattern can be recorded. 
 
Due to the high density of labels, the work in our lab has focused 
on extracting high resolution localization information from the 
DNA molecules.[19c, 20f] To be able to extract high resolution 
localization information from the DNA it is important that the 
molecules are fixed on the surface. One method for stretching 
DNA molecules on a surface is based on flow stretching and 
attaching the stretched DNA on a poly-L-lysine surface. In one 
such example bacteriophage T7 (40 kbp) labeled with M.BseCI 
(recognition sequence: 5’-ATCGAT-3’) and a biotin containing 
aziridine analogue was coupled to streptavadin-coated quantum 
dots. The DNA molecules were subsequently stretched on the 
surface using a capillary flow.[49c] Due to the sparse labeling, the 
labels could be easily localized. However, the localization 
suggests there is a large variation in the positioning due to 
deposition inhomogeneity. An alternative method for stretching 
DNA is based on DNA combing, a method developed by 
Bensimon et. al. in the 90s.[78] With this approach, DNA 
transalkylation using AdoMet analogues carrying either terminal 
amine or alkyne groups was directed with  the M.HhaI and M.TaqI 
(recognition sequences 5’-TCGA-3’ and 5’-GCGC-3’) 
methyltransferases. This gave a high density of modified sites 
which were subsequently labelled using the NHS-ester- or azide-
derivatives of the Atto647N dye. Following deposition, high 
resolution were created based on stochastic photobleaching and 
localization of individual emitters.[76a] This resulted in an 
approximate resolution of 42nm (approximately 80 base pairs).[19c] 
Both these methods suggest promising new technique for 
extracting sequence information from DNA molecules by studying 
the positon of MTase-directed labels on DNA. One such example 
is the typing of bacteriophage molecules based on the barcode 
embedded in the molecule. Another area could be the detection 
of copy number variation, repeats of large genomic elements in 
the genomes which are hard to find by sequencing.[76a] Finally, the 
MTase-based labeling approach can easily be combined with 
other genomic analysis approaches such as fluorescence in situ 
hybridization (FISH). 
 
DNA localization and spatially resolved transcriptomics 
The attachment of reporter groups to biomolecules allows for their 
localization in situ. This has enabled researchers to put detailed 
functional analysis of biological processes in a spatial context, 
allowing biological function, i.e. molecular genetics and 
biochemistry, to be correlated with information on biological 
structure obtained from e.g. embryology and histology.[79] 
Fluorescent labeling of nucleic acids such as DNA is one of the 
easiest routes to their localization in cells and many methods in 
fact exist.[80] However, methyltransferase directed transfer of 
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fluorescent groups offers the particular advantage that it allows 
for controlled targeting of the label and its covalent attachment. 
In an example from the group of Weinhold, the covalent coupling 
of Cy3 dyes using an N-adenosylaziridine cofactor to pUC19 and 
pBR322 plasmids was used.[51] In this study, the labeled plasmids 
are successfully transfected in CHO-k1 cells. Of these transfected 
cells, 25% of the cells showed a high Cy3 fluorescence intensity 
in the nucleus, despite the absence of nuclear import sequence 
on the plasmids.[51] 
It can be envisioned that MTase based labeling strategies could 
equally contribute to facilitate the in situ study of and large scale 
regulatory networks or efforts in highly multiplexed gene 
transcription profiling such as recently demonstrated by the team 
of Zhuang (Figure 5).[81] Here, the authors used an elaborate 
library of hybridization probes, fluorescently labeled and designed 
to target specific RNA species. By designing multiple, differently 
labeled probes, and multiple rounds of hybridization the authors 
were able to impart a unique color encoding for tens to even 
hundreds of individual RNA species in situ (Figure 5). 
 
Figure 5. In the highly multiplexed RNA profiling method of the Zhuang group[81] 
hundreds of individual mRNA can correctly be identified, and localized in situ. 
Although this example constitutes a great technical and scientific 
feat, the requirement to design and subsequently use 
hybridization probes can prove challenging and indeed, the 
authors had to apply significant error correction concepts 
borrowed from computer data encoding to their design of the 
probes. Furthermore, although this study allowed for 
simultaneous tracking of large numbers of biomolecular species, 
it was still only limited to RNA. Therefore, the possibility of 
achieving of highly directed MTase mediated labeling of all major 
classes of biomolecules opens up enticing new prospects to apply 
massively parallel observation of all species in an effort to truly 
unravel complex, spatially organized regulatory networks to 
elucidate cell-to-cell variations in the context of whole tissues.[79] 
 
 
3.3 Epigenetic analysis 
Epigenetic regulation is a collective term used to denote the entire 
spectrum of processes that modulate gene activity in an organism 
without actually altering the genetic sequence itself. Cytosine 
methylation (5mC) and stepwise conversion of 5mC to 
hydroxymethyl- (5hmC), formyl- (5fC) and finally carboxyl (5caC) 
cytosine in TET enzyme mediated demethylation are common in 
mammalian cells.[82] These modifications play important roles in 
embryonic development, stem-cell differentiation, genomic 
imprinting, neuronal function and cancer.[83] Additionally, histones 
and transcription factors can also be modified through methylation, 
acylation or phosphorylation.[84] Because of their role in 
methylation, MTases, together with suitable AdoMet analogues 
are the ideal tools to study these diverse and transient 
phenomena. 
 
DNA methylation 
Bisulfite conversion is a commonly used method for the detection 
of 5mC as well as the other cytosine modifications. It relies on 
chemical modification of target species followed by PCR or 
sequencing based quantification.[83, 85] Unfortunately, the method 
suffers from the relatively low sensitivity, particularly for low 
abundance modifications as well as the relatively high error 
rates.[83] Furthermore, the method only provides ensemble 
averaged information whereas the stochastic nature of DNA 
methylation calls for approaches with single cell resolution.[86] 
Here, single molecule detection methods can offer a solution. In 
one example, the methylation status of single DNA molecules was 
probed using restriction enzymes, whose activity is blocked by the 
methylated target base. Combining this with optical mapping 
results in a methylation map of the DNA.[87] More recently, methyl-
CpG binding proteins were used on DNA stretched in 
nanochannels.[88] Allowing for the direct detection of the 
methylation status of single molecules. A more direct method was 
used for the detection of hydroxymethyl cytosine. Here, the 
enzyme T4 b-glucosyltransferase was used to attach glucose 
molecules with a reactive azide moiety to the hydroxymethyl 
group, which could subsequently be coupled with fluorescent 
dyes.[89] For a more complete overview of the field the reader is 
referred to several excellent reviews.[76] 
Like restriction enzymes, a methylated base also blocks the 
activity of methyltransferases. This characteristic was recently 
explored in a recent paper that showed profiling of the DNA 
unmethylome.[50] Unmethylated sites were labeled with the CpG 
MTase, M.SssI, and an AdoMet analogue containing either an 
azide or amine functionality. The labeled DNA was then coupled 
to biotin (biotin-azide or biotin-NHS-ester) and extracted using 
streptavidin coated microbeads. After purification the DNA was 
analyzed using microarrays (Figure 6). This approach suggests a 
relatively straightforward way of enriching and subsequent 
sequencing of non-methylated DNA. Because of the sensitivity of 
the MTase-based method, very low amounts of DNA (100-300 ng) 
were needed to complete the analysis. Furthermore, the method 
was particularly sensitive to regions in the genome with low CpG 
presence, something that is difficult for other enrichment 
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techniques such as MeDIP (Methylated DNA immune-
precipitation) and MBD (Methyl-CpG-binding domain capture).[50] 
MTase-based labeling of methylated DNA could easily be 
combined with single molecule detection in nanochannels.[76b] 
Since MTase-based labeling can be targeted towards either 
adenine or cytosine bases, the method could be combined with 
optical mapping in order to localize the regions of (un)methylation. 
Epigenome mapping could then be a dual color approach, one 
color for the map of the DNA and one color to create a map of the 
(un)methyl map. 
 
Figure 6. General principle for capture based unmethylome detection, 
illustrated with a quantitative PCR assay 
Protein methylation 
The target substrates of protein methyltransferases have been 
extensively studied by the group of Luo through the development 
of an assay termed Bio-orthogonal Profiling of Protein Methylation 
(BPPM). Cells are transfected with a mutated protein MTase 
showing reduced preference for natural AdoMet compared to the 
analogue. Upon lysis, the mixture is incubated with a doubly-
activated AdoMet analogue with an azide linker. Target proteins 
are then coupled to a clickable dye such as e.g. 
dibenzylcyclooctyne coupled dyes and identified by mass 
spectrometry (MS) analysis or SDS-page (Figure 3).[21, 60-61] The 
approach was used for detecting the substrates of human protein 
MTase PRMT3, a protein MTase that preferably resides within the 
cytoplasm.[20a] Interestingly, while the protein MTase localizes in 
the cytoplasm, 23% of the modifications were found in the nucleus, 
suggesting a broader role for PRMT3. 
More recently, the team set out to study methylation status of 
histones in live cells by hijacking the enzymatic synthesis of 
AdoMet to create AdoMet analogues instead. A modified version 
of methionine carrying a clickable analogue (with a terminal 
alkyne) was transported into the cells and, together with ATP, 
processed by an engineered MAT to form the modified cofactor. 
This modified cofactor was then used by a mutant of G9a which 
successfully transferred the alkyne group to the histones. The 
transfer of alkyne group to histones was subsequently confirmed 
using LC/MS.[64] The authors subsequently used this method to 
attach clickable biotin to the labeled chromatin. This allowed them 
to enrich the labeled chromatin using streptavidin coated beads. 
After cleavage of the linker, the DNA attached to the histones 
could be purified and sent for sequencing.[64] Indeed, qPCR 
analysis confirmed the presence of several genes that resides on 
the targeted histones. Because of the structural similarity in 
different MTases, this method is expected to be applicable across 
a wide array of protein MTases with varying targets. For more 
details on the detection and analysis of protein methylation the 
reader is referred to one of several reviews on the topic.[90] 
Conclusions and future outlook 
Since the conception of labeling biomolecules using MTases, 
much work has been done. The method offers a simple solution 
for placing reporter molecules specifically and covalently on target 
biomolecules. So far the method has been convincingly shown 
with over 20 MTases, consisting of 9 DNA MTases, both adenine 
and cytosine DNA MTases, 4 RNA MTases and 11 protein 
MTases. Several mutated versions of DNA or protein MTases 
have been developed with improved activity for the various 
AdoMet analogues, and in some cases a preference of the MTase 
for the AdoMet analogue as opposed to the natural cofactor 
AdoMet. This preference of the MTase allows the method to be 
used in in vivo systems where the natural cofactor AdoMet is still 
present in the sample mixture. 
Two major groups of AdoMet analogues are currently available 
for MTase-based labeling. The aziridine based cofactors are 
synthesized chemically and can be used in MTase directed 
labeling reactions in which the whole compound is transferred to 
the substrate. The largest group of AdoMet analogues are the 
double-activated AdoMet analogues in which the transferrable 
methyl group of AdoMet is replaced by an unsaturated alkyl group 
that are used in mTag labeling of biomolecules. These analogues 
are typically synthesized from its precursor AdoHcy. Interestingly, 
these AdoMet analogue can sometimes also be synthesized by 
hijacking the same enzymes that create the natural cofactor 
AdoMet in cells, greatly simplifying the chemical route.  
This approach for targeted labeling of biomolecules can 
subsequently be used for all sorts of applications. The attachment 
of biotin or other chemical groups makes it possible to specifically 
capture low quantities of DNA, mRNA or proteins. Furthermore, 
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the method offers a way to covalently attach organic fluorescent 
molecules to target molecules, which makes it useful for detection 
using microscopy methods. Finally, the targeted labeling of DNA 
offers a way to analyze sequence information beyond the 
standard sequence reads, either by imaging far longer DNA 
molecules or by focusing on the epigenetic code embedded in the 
DNA molecule. 
The development of the methyltransferases as tools for 
biotechnology is a story that showcases the impact basic 
chemistry can have in this field. The emerging applications we 
have discussed highlight the potential of the MTase-directed 
reactions as a general strategy for targeting and labelling specific 
sites complex biological samples. There remains significant work 
to do to bring these tools to the non-specialist laboratory but the 
promise we have outlined is a strong driver for future development. 
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